Brief: Inventiva Randomizes First Patient In Nativ3 Clinical Trial In China
20/12/2023 21:27
Dec 20 (Reuters) - Inventiva SA IVAA.PA :
* INVENTIVA ANNOUNCES THE RANDOMIZATION OF THE FIRST PATIENT
IN
CHINA IN THE NATIV3 CLINICAL TRIAL AND PROVIDES AN UPDATE ON ITS
CLINICAL DEVELOPMENT PROGRAM
Source text for Eikon: ID:nGNXbQlhfk
Further company coverage: IVAA.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inventiva SA
See all newsFrance's Inventiva H1 net loss narrows
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Inventiva Announces Last Patient Visit In Nativ3 Phase 3 Clinical Trial Of Lanifibranor In Mash
Brief: Inventiva Announces Comprehensive Capital Structure Optimization Including Debt And Equity Financing In Advance Of The Anticipated Phase 3 Readout
Brief: Inventiva Secures Up To €150 Mln Debt Financing, Extends Debt Maturity To 2030